Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy.

Park HC, Xu ZG, Choi S, Goo YS, Kang SW, Choi KH, Ha SK, Lee HY, Han DS.

Nephrol Dial Transplant. 2003 Jun;18(6):1115-21.

PMID:
12748343
2.

Role of transforming growth factor-beta1 in the progression of chronic allograft nephropathy.

Campistol JM, Iñigo P, Larios S, Bescos M, Oppenheimer F.

Nephrol Dial Transplant. 2001;16 Suppl 1:114-6. Review.

PMID:
11369837
3.

Accurate measurement and clinical significance of urinary transforming growth factor-beta1.

Tsakas S, Goumenos DS.

Am J Nephrol. 2006;26(2):186-93. Epub 2006 May 4. Review.

4.

TGF-beta in blood: a complex problem.

Grainger DJ, Mosedale DE, Metcalfe JC.

Cytokine Growth Factor Rev. 2000 Mar-Jun;11(1-2):133-45. Review.

PMID:
10708961
5.

Steroids in the treatment of IgA nephropathy to the improvement of renal survival: a systematic review and meta-analysis.

Zhou YH, Tang LG, Guo SL, Jin ZC, Wu MJ, Zang JJ, Xu JF, Wu CF, Qin YY, Cai Q, Gao QB, Zhang SS, Yu DH, He J.

PLoS One. 2011 Apr 12;6(4):e18788. doi: 10.1371/journal.pone.0018788. Review.

6.

Omega-3 fatty acids ameliorate proteinuria but not renal function in IgA nephropathy: a meta-analysis of randomized controlled trials.

Chou HH, Chiou YY, Hung PH, Chiang PC, Wang ST.

Nephron Clin Pract. 2012;121(1-2):c30-5. doi: 10.1159/000341929. Epub 2012 Oct 19. Review.

PMID:
23095320
7.

Transforming growth factor beta activity in urine of patients with type 2 diabetes and diabetic nephropathy.

Rivarola EW, Moyses-Neto M, Dantas M, Da-Silva CG, Volpini R, Coimbra TM.

Braz J Med Biol Res. 1999 Dec;32(12):1525-8. Review.

8.

Association of T869, C509T, G915C gene polymorphism of transforming growth factor-β1 with IgA nephropathy risk.

Zhou TB, Guo XF, Yin SS.

Ren Fail. 2014 Jun;36(5):823-8. doi: 10.3109/0886022X.2014.890059. Epub 2014 Feb 24. Review.

PMID:
24564406
9.

Glycosaminoglycan treatment in glomerulonephritis? An interesting option to investigate.

Gambaro G, Kong NC.

J Nephrol. 2010 May-Jun;23(3):244-52. Review.

PMID:
20155726
10.
11.

Recognition and management of IgA nephropathy.

Ibels LS, Gyory AZ, Caterson RJ, Pollock CA, Mahony JF, Waugh DA, Coulshed S.

Drugs. 1998 Jan;55(1):73-83. Review.

PMID:
9463791
12.

Evaluation of hematuria, proteinuria, and hypertension in adolescents.

Mahan JD, Turman MA, Mentser MI.

Pediatr Clin North Am. 1997 Dec;44(6):1573-89. Review.

PMID:
9400588
13.

Should losartan be administered following brain injury?

Friedman A, Bar-Klein G, Serlin Y, Parmet Y, Heinemann U, Kaufer D.

Expert Rev Neurother. 2014 Dec;14(12):1365-75. doi: 10.1586/14737175.2014.972945. Epub 2014 Oct 27. Review.

PMID:
25346269
14.

[Urinary abnormalities in patients with hypertension].

Suzuki H.

Nihon Rinsho. 2000 Jan;58 Suppl 1:775-9. Review. Japanese. No abstract available.

PMID:
11026378

Supplemental Content

Support Center